Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma

• Published in: Brain sciences Vol. 12; no. 8; p. 980
• Main Authors: Gedvilaite, Greta, Vilkeviciute, Alvita, Glebauskiene, Brigita, Kriauciuniene, Loresa, Liutkeviciene, Rasa
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 25-07-2022; MDPI
• Subjects: Adenoma; Age; Biomarkers; Cancer; Disease; Enzymes; Epigenetics; Gene polymorphism; Hormones; Leukocytes; Magnetic resonance imaging; Medical prognosis; Mutation; Peripheral blood; Pituitary; pituitary adenoma; Proteins; rs35073794; Single-nucleotide polymorphism; Statistical analysis; Telomerase; telomerase complex; Telomeres; Transcription factors; Tumorigenesis; Tumors; New York; United States > US
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci12080980

Pituitary adenoma (PA) is the most common benign tumor of the pituitary gland. The pathogenesis of most PA is considered as a multifactorial process, that involves genetic mutations, alterations in gene transcription, and epigenetic factors. Their interaction promotes tumorigenesis. The processes are increasingly focused on changes in telomere length. Our study enrolled 126 patients with PA and 368 healthy subjects. DNA samples from peripheral blood leukocytes were purified by the DNA salting-out method. The RT-PCR carried out SNPs and relative leukocyte telomere lengths (RLTL). ELISA determined the level of TEP1 in blood serum. Binary logistic regression revealed that TERC rs35073794 is likely associated with increased odds of PA development and macro-PA development. It is also associated with decreased odds of active PA, non-invasive PA, and PA without relapse development. Also, we discovered that PA patients with at least one G allele of the TEP1 gene polymorphism rs1713418 have lower serum TEP1 levels than healthy individuals (p = 0.035). To conclude, the study revealed that TERC rs35073794 might be a potential biomarker for PA development.